×

Why US biotech stocks are back in favor

7:16 PM ET Mon, 25 Aug 2014

While biotechnology shares are not cheap, they are nowhere near "bubble-like" valuations, says Bill Stone, Chief Investment Strategist at PNC Asset Management Group.